Related references
Note: Only part of the references are listed.Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers
Tomasz Zaremba et al.
BIOCHEMICAL JOURNAL (2011)
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
Poulam M. Patel et al.
EUROPEAN JOURNAL OF CANCER (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Patterns of Expression of DNA Repair Genes and Relapse From Melanoma
Rosalyn Jewell et al.
CLINICAL CANCER RESEARCH (2010)
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2008)
Systemic therapy for metastatic malignant melanoma - from deeply disappointing to bright future?
Paul Lorigan et al.
EXPERIMENTAL DERMATOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma
Malcolm Ranson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase:: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors
M Ranson et al.
CLINICAL CANCER RESEARCH (2006)
Changing paradigms - An update on the multidisciplinary management of malignant glioma
Roger Stupp et al.
ONCOLOGIST (2006)
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma
TF Gajewski et al.
CLINICAL CANCER RESEARCH (2005)
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
JA Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes 6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1
ER Plummer et al.
CLINICAL CANCER RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
TK Eigentler et al.
LANCET ONCOLOGY (2003)
Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine
GP Margison et al.
MUTAGENESIS (2002)
DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis
C Bernstein et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2002)
Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls
SJ Pocock et al.
LANCET (2002)
Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
JA Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials
M Huncharek et al.
MELANOMA RESEARCH (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
